Los Angeles Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Los Angeles Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.14K	Hold	127	–	–	﹤0.01%	1977
2025 Q4	$7.98K	Buy	+127	New	+$7.11K	﹤0.01%	2156
2018 Q3	–	Sell	-5,488	Closed	-$4.02M	–	1454
2018 Q2	$4.02M	Sell	5,488 -375	-6%	-$432K	0.02%	528
2018 Q1	$9.35M	Buy	5,863 +3,258	+125%	+$4.2M	0.05%	330
2017 Q4	$2.33M	Buy	2,605 +1,782	+217%	+$1.05M	0.01%	629
2017 Q3	$296K	Buy	+823	New	+$257K	﹤0.01%	1153
2016 Q4	–	Sell	-742	Closed	-$191K	–	1212
2016 Q3	$191K	Sell	742 -261	-26%	-$67.2K	﹤0.01%	1170
2016 Q2	$214K	Buy	+1,003	New	+$224K	﹤0.01%	1141
2014 Q2	–	Sell	-1,388	Closed	-$252K	–	1260
2014 Q1	$252K	Buy	1,388 +664	+92%	+$131K	﹤0.01%	1119
2013 Q4	$123K	Sell	724 -2,158	-75%	-$348K	﹤0.01%	1246
2013 Q3	$451K	Sell	2,882 -50	-2%	-$9.24K	0.01%	953
2013 Q2	$508K	Buy	+2,932	New	+$450K	0.01%	904

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Los Angeles Capital Management's NKTR Position: Q1 2026 in Review

Los Angeles Capital Management held its Nektar Therapeutics (NKTR) position steady in Q1 2026 at 127 shares worth $9.14K. The position accounts for ﹤0.01% of the portfolio, ranked #1977.

Los Angeles Capital Management first reported a position in NKTR in Q2 2013 and has held it in 12 quarters since. The position peaked at $9.35M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

Los Angeles Capital Management held 127 shares of Nektar Therapeutics worth $9.14K as of Q1 2026.
Los Angeles Capital Management left its Nektar Therapeutics share count unchanged in Q1 2026.
Nektar Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1977 holding.
Los Angeles Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 12 quarters since.
Los Angeles Capital Management's Nektar Therapeutics position peaked at $9.35M in Q1 2018.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.